Positive topline results from Hong Kong-based Ascletis Pharma’s ongoing phase I US clinical trial indicate the best-in-class potential of its oral small molecule IL-17 inhibitor ASC50.
Positive topline results from Hong Kong-based Ascletis Pharma’s ongoing phase I US clinical trial indicate the best-in-class potential of its oral small molecule IL-17 inhibitor ASC50.